（编辑 袁冠琳） 证券日报网讯 1月30日，广生堂在互动平台回答投资者提问时表示，本次在AASLD年会上的报告，是 公司在乙肝治疗领域创新药研发进展的一次重要展示，有助于该研究成果获得国际肝病学术领域的关 注，促进了友好的国际交流和合作探讨。公司将继续稳步推进相关乙肝创新药临床研发工作，依规及时 履行创新药进展的信息披露义务。 ...

Core Viewpoint - The 76th American Association for the Study of Liver Diseases (AASLD) annual meeting highlighted significant advancements in hepatitis B treatment, particularly through the innovative drug Hepcludex developed by Shanghai Hepu Pharmaceutical, which has shown promising results in clinical trials [1] Group 1: Clinical Trial Results - Hepcludex has achieved breakthrough progress in its Phase II randomized double-blind clinical trial for chronic hepatitis B [1] - The drug demonstrated the ability to reverse interferon resistance in patients with "big three positive" hepatitis B, a significant milestone in treatment [1] - Some patients in the trial achieved cccDNA clearance, meeting the highest international standard for hepatitis B cure known as sterilizing cure [1]

Core Viewpoint - Guangshentang (300436) is actively conducting Phase III clinical trials for its innovative hepatitis B drug, Nairu Kewei GST-HG141, targeting patients with poor antiviral response to chronic hepatitis B (CHB) treatment [1] Company Summary - The company is focusing on the development of Nairu Kewei GST-HG141 as a combination therapy for chronic hepatitis B patients [1] - The research scope of the drug does not include treatment for hepatitis C (HCV) [1]